IRCT201105084849N2
已完成
3 期
The comparison of metformin, pioglitazon and Silymarin on biochemical indices in patient with nonalcoholic fatty liver
Vice-Cancellor for Research of Qazvin University of Medical Science0 个研究点目标入组 66 人待定
概览
- 阶段
- 3 期
- 干预措施
- 未指定
- 疾病 / 适应症
- 未指定
- 发起方
- Vice-Cancellor for Research of Qazvin University of Medical Science
- 入组人数
- 66
- 状态
- 已完成
- 最后更新
- 8年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •inclusion criteria; patients with NASH;
- •rising of AST and ALT; evidence of fatty liver in ultrasound
- •and exclusion criteria; DM; Alchole drinking; HBS Ag; HCV Ab
排除标准
- 未提供
结局指标
主要结局
未指定
相似试验
已完成
4 期
To study the differences in the effects of various drugs in patients suffering from metabolic syndrome, which is a cluster of conditions such as obesity, increased blood pressure and disordered cholesterol levels that increases the risk of heart diseases, diabetes and stroke.Health Condition 1: null- Metabolic SyndromeCTRI/2014/10/005139Department of Pharmacology140
已完成
不适用
Comparative Efficacy of Pioglitazone and Metformin in Glucose Variability in Type 2 Diabetestype 2 diabetesJPRN-UMIN000001891Jikei University School of Medicine20
进行中（未招募）
不适用
Impact of Pioglitazone, Metformin and the combination of both on cardiovascular risk in insulin-treated patients with Type 2 diabetes – The PIOcomb Study - PIOcomb StudyEUCTR2007-006706-14-ATTakeda Pharma GmbH200
进行中（未招募）
不适用
Impact of Pioglitazone, Metformin and the combination of both on cardiovascular risk in insulin-treated patients with Type 2 diabetes – The PIOcomb Study - PIOcomb StudyDiabetes mellitus type 2MedDRA version: 9.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusEUCTR2007-006706-14-DETakeda Pharma GmbH
已完成
不适用
Evaluation of possible cause of weight change after Metformin and pioglitazone administration in patients with type 2 diabetesIRCT201102275917N1Vice chancellor for Research, Tehran university of medical science (TUMS)60